Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada

Osteoporosis International

Volumn 23, Issue 3, 2012, Pages 1075-1082

  Burden, A M ^a   Paterson, J M ^b,c,d,e   Solomon, D H ^f   Mamdani, M ^a,b,c,g   Juurlink, D N ^h   Cadarette, S M ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h Sunnybrook Health Sciences Centre   (Canada)

Author keywords

Alendronate; Etidronate; Medication persistence; Osteoporosis; Risedronate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; RISEDRONIC ACID;

AGED; ARTICLE; CANADA; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG PRESCRIPTIONS; DRUG SUBSTITUTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; ONTARIO; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PHYSICIAN'S PRACTICE PATTERNS; TIME FACTORS;

EID: 84857442741     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1645-7     Document Type: Article

References (33)

1. R Burge B Dawson-Hughes DH Solomon, et al. 2007 Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 J Bone Miner Res 22 465 475 17144789 10.1359/jbmr.061113 (Pubitemid 46797130)
2. C MacLean S Newberry M Maglione, et al. 2008 Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis Ann Intern Med 148 197 213 18087050 (Pubitemid 351665507)
3. Brown JP, Josse RG, Scientific Advisory Council of the Osteoporosis Society of Canada 2002 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada Can Med Assoc J 167 10 Suppl S1 S34
4. SB Jaglal I Weller M Mamdani, et al. 2005 Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? J Bone Miner Res 20 898 905 15883628 10.1359/JBMR.041231 (Pubitemid 40712812)
5. I Imaz P Zegarra J Gonzalez-Enriquez, et al. 2010 Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis Osteoporos Int 21 1943 1951 19967338 1:CAS:528:DC%2BC3cXht1Wmu77K 10.1007/s00198-009-1134-4
6. ES Siris PL Selby KG Saag, et al. 2009 Impact of osteoporosis treatment adherence on fracture rates in North America and Europe Am J Med 122 S3 S13 19187810 10.1016/j.amjmed.2008.12.002
7. MM Wilkes RJ Navickis WW Chan EM Lewiecki 2010 Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials Osteoporos Int 21 1943 1951 10.1007/s00198-009-0991-1
8. SM Cadarette DH Solomon JN Katz AR Patrick MA Brookhart 2011 Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors Osteoporos Int 22 943 954 20532481 1:STN:280:DC%2BC3M7nt1OntA%3D%3D 10.1007/s00198-010-1309-z
9. A Papaioannou CC Kennedy L Dolovich E Lau JD Adachi 2007 Patient adherence to osteoporosis medications: problems, consequences and management strategies Drugs Aging 24 37 55 17233546 1:CAS:528:DC%2BD2sXjt1Kht7w%3D 10.2165/00002512-200724010-00003 (Pubitemid 46148080)
10. P Kothawala E Badamgarav S Ryu RM Miller RJ Halbert 2007 Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis Mayo Clin Proc 82 1493 1501 18053457 10.4065/82.12.1493 (Pubitemid 350211697)
11. M Melo F Qiu K Sykora, et al. 2006 Persistence with bisphosphonate therapy in older people J Am Geriatr Soc 54 1015 1016 16776810 10.1111/j.1532-5415.2006.00758.x (Pubitemid 43847052)
12. JA Cramer DT Gold SL Silverman EM Lewiecki 2007 A systematic review of persistence and compliance with bisphosphonates for osteoporosis Osteoporos Int 18 1023 1031 17308956 1:CAS:528:DC%2BD2sXntVOlsrY%3D 10.1007/s00198-006-0322-8 (Pubitemid 47019996)
13. SM Cadarette AM Burden 2010 Measuring and improving adherence to osteoporosis pharmacotherapy Curr Opin Rheumatol 22 397 403 20498602 10.1097/BOR.0b013e32833ac7fe
14. JM Paterson A Suleiman JE Hux C Bell 2008 How complete are drug history profiles that are based on public drug benefit claims? Can J Clin Pharmacol 15 e108 e116 18283220
15. Williams JI, Young W (1996) Appendix 1: A summary of studies on the quality of health care administrative databases in Canada. In: Goel V, Williams JI, Anderson GM, Blackstein-Hirsch P, Fooks C, Naylor CD (eds) Patterns of health care in Ontario, The ICES Practice Atlas. Canadian Medical Association, Ottawa
16. Richards J, Brown A, Homan C (2001) The data quality study of the Canadian Discharge Abstract Database. In Proceedings of Statistics Canada Symposium.
17. Juurlink D, Preyra C, Croxford R et al (2006) Canadian institute for health information discharge abstract database: a validation study. In ICES investigative report. Institute for Clinical Evaluative Sciences, Toronto
18. Cadarette SM, Jaglal SB, Raman-Wilms L, Beaton DE, Paterson JM (2011) Osteoporosis quality indicators using healthcare utilization data. Osteoporos Int 22:1335-1342
19. Ministry of Health and Long-Term Care (2005) Ontario Drug Benefit formulary/comparative drug index. In. Ministry of Health, Queen's Printer for Ontario
20. MA Brookhart J Avorn JN Katz, et al. 2007 Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance Am J Med 120 251 256 17349448 10.1016/j.amjmed.2006.03.029 (Pubitemid 46341156)
21. JA Cramer MM Amonkar A Hebborn R Altman 2005 Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 1453 1460 16197664 1:CAS:528:DC%2BD2MXhtFKqu7zP 10.1185/030079905X61875 (Pubitemid 41368578)
22. JC Lo AR Pressman MA Omar B Ettinger 2006 Persistence with weekly alendronate therapy among postmenopausal women Osteoporos Int 17 922 928 16609824 1:CAS:528:DC%2BD28XkvVCnurY%3D 10.1007/s00198-006-0085-2 (Pubitemid 43781507)
23. DH Solomon J Avorn JN Katz, et al. 2005 Compliance with osteoporosis medications Arch Intern Med 165 2414 2419 16287772 10.1001/archinte.165.20.2414 (Pubitemid 41640855)
24. P Geusens 2009 Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment Curr Osteoporos Rep 7 12 17 19239824 10.1007/s11914-009-0003-6
25. DM Black AV Schwartz KE Ensrud, et al. 2006 Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial JAMA 296 2927 2938 17190893 1:CAS:528:DC%2BD2sXnvVGh 10.1001/jama.296.24.2927 (Pubitemid 46021497)
26. NB Watts A Chines WP Olszynski, et al. 2008 Fracture risk remains reduced one year after discontinuation of risedronate Osteoporos Int 19 365 372 17938986 1:CAS:528:DC%2BD1cXhtlOqsb4%3D 10.1007/s00198-007-0460-7 (Pubitemid 351199181)
27. JR Curtis AO Westfall H Cheng E Delzell KG Saag 2008 Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday Osteoporos Int 19 1613 1620 18483689 1:STN:280:DC%2BD1cnksVCrsA%3D%3D 10.1007/s00198-008-0604-4
28. A Cranney G Guyatt L Griffith, et al. 2002 IX: summary of meta-analyses of therapies for postmenopausal osteoporosis Endocr Rev 23 570 578 12202472 1:CAS:528:DC%2BD38Xnt1Whs78%3D 10.1210/er.2001-9002 (Pubitemid 34925651)
29. Jaglal SB (2002) Bone mineral density testing. In: Stewart DE, Ferris L, Hyman I, Cohen M, Williams JI, Cheung A (eds) Ontario women's health status report. Institute for Clinical Evaluative Sciences, Toronto
30. R Tamblyn T Reid N Mayo P McLeod M Churchill-Smith 2000 Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment J Clin Epidemiol 53 183 194 10729691 1:STN:280:DC%2BD3c7psFOjsg%3D%3D 10.1016/S0895-4356(99)00136-5 (Pubitemid 30151224)
31. B Cryer DC Bauer 2002 Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 77 1031 1043 12374247 10.4065/77.10.1031
32. E Shane D Burr PR Ebeling, et al. 2010 Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American society for bone and mineral research J Bone Miner Res 25 2267 2294 20842676 10.1002/jbmr.253
33. Cadarette SM, van Wijk BL, Patrick AR, Brookhart MA (2011) Adherence to pharmacotherapy for hypercholesterolemia, hypertension and osteoporosis: behavioral insights. Am J Pharm Ben, in press